XEOMIN® (incobotulinumtoxinA) for Adults with Upper Limb Spasticity

An estimated 12 million adult patients worldwide suffer from spasticity.

At Merz—the company behind XEOMIN—we understand the struggles and the unique needs of adult patients with upper limb spasticity. We are committed to helping you achieve a better patient experience. We recognize that you have your own unique goals and aspirations. We want to help you focus on your next adventure, next achievement, or next opportunity—not your symptoms.

How it works1

Upper Limb Spasticity icon

In adults with upper limb spasticity there is an imbalance of signals from the brain to the muscles, which causes stiffness and spasms. This can lead to abnormal arm or hand positions, uncomfortable movement, and pain.2

Upper Limb Spasticity injection icon

XEOMIN is injected into muscles to help interfere with these signals. This helps decrease muscle stiffness and improve your ability to function using the affected muscles.1

Upper Limb Spasticity after icon

Some stiffness and spasms may still occur, but less severely.

Merz is committed to helping adult patients manage their upper limb spasticity.

In clinical studies, XEOMIN significantly improved muscle tone compared with a nontherapeutic injection, known as a placebo, as measured at week 4 after initiating treatment.

The Global Impression of Change Scale (GICS) is a global measure of a patient’s functional improvement. When investigators rated how much overall change in spasticity they saw in each patient following treatment with XEOMIN1:

References

  1. XEOMIN® [package insert]. Raleigh, NC: Merz North America, Inc; 2018.
  2. Differential diagnosis for spasticity. Neuro Rehab Resource website. http://www.neurorehabresource.org/Files/NRR_Differential_Diagnosis.pdf. Accessed October 7, 2015.